DMAA - NASDAQ

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA·NASDAQ

$10.61

+0.094%

Financial ServicesShell Companies

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$357.74M

EPS0.1900

P/E Ratio55.84

Earnings Date—

No Revenue Data

DMAA has not reported any revenue values in the available annual periods.

5.94M

Net Income

-1240318%

3Y-1240318.0%

5Y-1240318.0%

10Y-1240318.0%

-539.19K

Operating Cash Flow

182675%

3Y+182675.0%

5Y+182675.0%

10Y+182675.0%

Drugs Made In America Acquisition Corp. Ordinary Shares Profit Bridge

DMAA · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (0.00)

Gross Profit0.00

Operating Expenses

Operating Expenses (2.82M)

Operating Income-2.82M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense8.76M

Pretax Income5.94M

Income Tax (0.00)

Net Income5.94M

Net Income

5.94M

Profitability Analysis

Drugs Made In America Acquisition Corp. Ordinary Shares Income Statement

DMAA • NASDAQ

Drugs Made In America Acquisition Corp. Ordinary Shares Income Statement	Dec 2025	Dec 2024
REVENUE
GROSS PROFIT
OPERATING INCOME
Operating Expenses	(2.8M)	(479.0)
Selling, General & Administrative	(2.8M)	(479.0)
Operating Income	-2.8M	-479.0
PRE-TAX INCOME
Net Interest Income	8.8M	0.0
Total Other Income Expenses Net	8.8M	0.0
Income Before Tax	5.9M	-479.0
NET INCOME
Net Income	5.9M	-479.0

SEC Filings

DMAA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	April 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 01, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 22, 2026	2026	View Filing
10-K 10-K 2025 FY FY	April 15, 2026	December 31, 2025	2025	View Filing
DEF 14A DEF 14A 2026 N/A	April 14, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 08, 2026	April 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	February 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 06, 2026	2026	View Filing

Showing 1 to 10 of 26 filings

Related Guides

Blog Categories

Continue your DMAA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.